AzTrials
AzTrials

Obstructive Sleep Apnea (OSA)NCT02295306

Overnight Polysomnography and Respiratory Volume Monitor

An observational study of Obstructive Sleep Apnea (OSA), run by Tufts Medical Center at 1 site in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

Sleep disordered breathing; specifically obstructive sleep apnea (OSA) is a disease affecting 8-12% of the general population and often more than 70% of the bariatric surgical population. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Obstructive Sleep Apnea (OSA)
What is being tested?
Respiratory Volume Monitor (RVM, ExSpiron)
Type of treatment
Medical device
How many people
80 participants
Where
1 siteUnited States
Study dates
Jun 2013to 31 Jul 2028
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All adult patients referred to the sleep laboratory at Tufts Medical Center for a standard polysomnogram (PSG) are eligible to be recruited.

Who may be able to join

  • Adult Patients referred to the sleep lab for a polysomnography for suspicion of sleep disordered breathing aged ≥ 18 years. Ability to provide written informed consent.

Who cannot join

  • Patients not competent to give informed consent, patients with implantable electronic devices, such as pacemakers, stimulators, etc. pregnant or lactating women.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Tufts Medical Center

    Boston, Massachusetts, 02111

Other trials in United States

About this study

Official title: The Evaluation of a Respiratory Volume Monitor in Patients Undergoing Overnight Polysomnography

Sleep disordered breathing; specifically obstructive sleep apnea (OSA) is a disease affecting 8-12% of the general population and often more than 70% of the bariatric surgical population. OSA is characterized by the repetitive collapse of the upper airway, causing a reduction or cessation in airflow and decreases in oxygen saturation. These events are resolved by arousals from sleep, reducing sleep quality and leading to excessive daytime sleepiness. An in-laboratory polysomnography (PSG) is the gold standard for the diagnosis of OSA.

Previous studies have established obstructive sleep apnea (OSA) as a potential independent risk factor for postoperative complications, adverse surgical outcomes, and longer hospital stays.

Read more

Patients with OSA have an increase in postoperative complications, the most frequent being oxygen desaturation, postoperative atelectasis and increased postoperative pain. Despite the clear risks, OSA remains under diagnosed with an estimated 25-30% of patients at a high risk for OSA. It has been suggested that OSA events may be even more frequent post operatively because of the residual effects of anesthesia and the use of potent pain medications such as opioids. Postoperatively apneas often go undetected and untreated. The use of supplemental O2 may mask any desaturations and there is no convenient technology to noninvasively monitor ventilation to detect apnea and hypopnea in post-surgical patients.

New advances in technology and digital signal processing have led to the development of an impedance based Respiratory Volume Monitor (RVM). The RVM (ExSpiron™, Respiratory Motion, Inc.; Waltham, MA) has been shown to provide accurate real-time, continuous, non-invasive measurements of tidal volume (TV), minute ventilation (MV) and respiratory rate (RR). Our main hypotheses are that the non-invasive, impedance-based RVM monitor will accurately reflect TV, RR and MV during sleep and will detect apneas and hypopneas accurately.

Read the detailed description

This is an observational pilot study to evaluate the clinical applicability of the ExSpiron Respiratory Volume Monitor (RVM) in patients with suspected sleep apnea. Previous work has demonstrated the ability of the RVM to provide non-invasive, real-time, continuous measurements of respiratory parameters (MV, TV, and RR) but those studies have not specifically looked at patients during sleep or patients with sleep disordered breathing.

Previously there was no device capable of providing, continuous, non-invasive, real time measurements of ventilatory status such as minute ventilation, tidal volume and RR. The ExSpiron system utilizing impedance based technology and proprietary algorithms (Respiratory Motion Inc., Waltham, MA) have been developed to obtain these measurements.

Respiratory Motion, Inc. has previously evaluated ExSpiron measurements of respiratory parameters (MV, TV and RR) in studies of adult volunteer subjects. Stimulus leads delivered an alternating minimal current (1.5 mA) at a frequency of 50 kHz and recording leads recorded differential voltages to calculate impedance. Subject data (height, weight, age, gender, chest circumference) were measured. The studies showed that using the optimal lead placement configuration, algorithms based on chest wall impedance and respiratory pattern analysis provided provided RVM measurements and ExSpiron curves which correlated strongly with spirometry volumes and spirometry curves.

A large percentage of patients in the general surgical population have undiagnosed OSA. This population is at increased risk of adverse perioperative respiratory complications. Assessment and management of perioperative respiratory function and early intervention when indicated is a multifaceted, complex task often complicated by the unavailability of an accurate and continuous monitoring system that can demonstrate apnea and hypopnea to guide clinical decision making. The ExSpiron system is designed for these patients and is intended to address some of the limitations of the current generation of hospital monitors as listed below:

In the, non-ventilated patient, current monitoring devices do not provide objective non-invasive, continuous real time measurements of important respiratory parameters MV, TV and RR that reflect respiratory competence, nor do they provide adequate assessment of apnea and hypopnea.

Current monitoring of non-intubated patients mostly relies on oximetry data, subjective clinical assessment which measures respiration and not ventilation and rarely transcutaneous CO2 measurements. In appropriate clinical settings, the ExSpiron system can provide direct quantitative measure of ventilation (MV, TV and RR) that can be used in the detection of apnea and hypopnea.

Precise apnea and hypopnea assessment.

Most if not all of the gaps left by current respiratory assessment technologies may be filled by a non-invasive monitor such as the one proposed for use in this study. There are many potential applications for this technology including: use in peri-procedural environment to evaluate the effects of medication on ventilation and detection of apnea/hypopnea. In addition, it may be useful in clinical decision making regarding medication adjustments of pain management protocols, evaluation ventilatory status prior to extubation and evaluation of the need for reintubation, but also trending of respiratory patterns to avoid risky emergency airway management interventions.

New advances in technology and digital signal processing have led to the development of an impedance based Respiratory Volume Monitor (RVM). The RVM (ExSpiron™, Respiratory Motion, Inc.; Waltham, MA) has been shown to provide accurate real-time, continuous, non-invasive measurements of tidal volume (TV), minute ventilation (MV) and respiratory rate (RR). Our main hypotheses are that the non-invasive, impedance-based RVM monitor will accurately reflect TV, RR and MV during sleep and will detect apneas and hypopneas accurately.

Main Hypothesis: The ExSpiron monitor accurately reflects apnea and hypopnea events compared to standard polysomnography. The ExSpiron monitor is able to distinguish between central and obstructive apneic events.

Secondary Hypothesis: 1) Correlation of MV% as compared to % predicted with comorbidities (e.g. hypertension and metabolic syndrome), 2)Correlation of MV changes as compared to MV% predicted with oxygen desaturation index (ODI), 3) evaluation breathing patterns before and after obstruction, 4) evaluation of breathing patterns in different types of apnea (central, obstructive and mixed).

Being tested
Respiratory Volume Monitor (RVM, ExSpiron)
Keywords
OSA, polysomnography, ExSpiron monitor
Medical subject headings
Sleep Apnea, Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Respiratory Volume Monitor (RVM, ExSpiron)Device

    Connecting patient to the ExSpiron monitor and continuous ExSpiron data collection during the patient's polysomnography (PSG)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Agreement between number and duration of apnea events measured as AHI (apnea hypopnea index) assessed by standard polysomnography versus Exspiron monitor

    Measured: Duration of polysomnography study, usually 1 overnight assessment

Secondary outcomes (1)
  1. Ability of the Exspiron monitor to distinguish between central and obstructive apnea events. There is no unit measurement for this comparison

    Measured: Duration of polysomnography study, usually 1 overnight assessment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Nov 2014 (estimated)
  2. Study startJun 2013
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Jul 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02295306
Sponsor's protocol ID
IRB # 10880
Status last verified
Sep 2026
First submitted
26 Sep 2014
Last updated
5 Oct 2026
Results posted
No
Data monitoring committee
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in